Literature DB >> 25146439

Nanomedicines based drug delivery systems for anti-cancer targeting and treatment.

Vikas Jain1, Shikha Jain, S C Mahajan.   

Abstract

Cancer is defined as an uncontrolled growth of abnormal cells. Current treatment strategies for cancer include combination of radiation, chemotherapy and surgery. The long-term use of conventional drug delivery systems for cancer chemotherapy leads to fatal damage of normal proliferate cells and this is particularly used for the management of solid tumors, where utmost tumor cells are not invaded quickly. A targeted drug delivery system (TDDS) is a system, which releases the drug at a preselected biosite in a controlled manner. Nanotechnology based delivery systems are making a significant impact on cancer treatment and the polymers play key role in the development of nanopraticlulate carriers for cancer therapy. Some important technological advantages of nanotherapeutic drug delivery systems (NDDS) include prolonged half-life, improved bio-distribution, increased circulation time of the drug, controlled and sustained release of the drug, versatility of route of administration, increased intercellular concentration of drug and many more. This review covers the current research on polymer based anticancer agents, the rationale for development of these polymer therapeutical systems and discusses the benefits and challenges of cancer nanomedicines including polymer-drug conjugates, micelles, dendrimers, immunoconjugates, liposomes, nanoparticles.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25146439     DOI: 10.2174/1567201811666140822112516

Source DB:  PubMed          Journal:  Curr Drug Deliv        ISSN: 1567-2018            Impact factor:   2.565


  19 in total

Review 1.  MET: roles in epithelial-mesenchymal transition and cancer stemness.

Authors:  Hye-Min Jeon; Jeongwu Lee
Journal:  Ann Transl Med       Date:  2017-01

2.  Preparation and Release of pH-Sensitive β-Cyclodextrin Derivative Micelles Loaded with Paclitaxel.

Authors:  Meirong Zhao; Weiwei Jiang; Xinrong Xie; Yogini Jaiswal; Leonard Williams; Mei Wei; Ying Mo; Yifu Guan; Hua Yang
Journal:  Polymers (Basel)       Date:  2022-06-18       Impact factor: 4.967

Review 3.  Emerging Roles of Electrospun Nanofibers in Cancer Research.

Authors:  Shixuan Chen; Sunil Kumar Boda; Surinder K Batra; Xiaoran Li; Jingwei Xie
Journal:  Adv Healthc Mater       Date:  2017-12-06       Impact factor: 9.933

4.  Enhanced anti-tumor effects of doxorubicin on glioma by entrapping in polybutylcyanoacrylate nanoparticles.

Authors:  Yuebin Zhang; Jia Yu; Lifeng Zhang; Jiabin Cai; Doute Cai; Chengjie Lv
Journal:  Tumour Biol       Date:  2015-09-24

5.  Paclitaxel-loaded nanobubble targeted to pro-gastrin-releasing peptide inhibits the growth of small cell lung cancer.

Authors:  Jin-Ping Wang; Ji-Ping Yan; Jing Xu; Ting-Hui Yin; Rong-Qin Zheng; Wei Wang
Journal:  Cancer Manag Res       Date:  2019-07-16       Impact factor: 3.989

Review 6.  Electrospun Nanofibers for Cancer Therapy.

Authors:  Huanhuan Luo; Tianyang Jie; Li Zheng; Chenglong Huang; Gang Chen; Wenguo Cui
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

7.  Supramolecular Tripeptide Hydrogel Assembly with 5-Fluorouracil.

Authors:  Evelina Parisi; Ana M Garcia; Domenico Marson; Paola Posocco; Silvia Marchesan
Journal:  Gels       Date:  2019-01-26

Review 8.  Recent Advances in Hydrogel-Based Drug Delivery for Melanoma Cancer Therapy: A Mini Review.

Authors:  Sowmya Vishnubhakthula; Ravinder Elupula; Esteban F Durán-Lara
Journal:  J Drug Deliv       Date:  2017-08-09

Review 9.  State of the Art of Stimuli-Responsive Liposomes for Cancer Therapy.

Authors:  Elmira Heidarli; Simin Dadashzadeh; Azadeh Haeri
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

10.  Hypocrellin B-loaded, folate-conjugated polymeric micelle for intraperitoneal targeting of ovarian cancer in vitro and in vivo.

Authors:  Jie Li; Shu Yao; Kai Wang; Zaijun Lu; Xuantao Su; Li Li; Cunzhong Yuan; Jinbo Feng; Shi Yan; Beihua Kong; Kun Song
Journal:  Cancer Sci       Date:  2018-05-07       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.